HR (95% CI) | ||||||

Change-point | Month 18 (day 540) | Month 24 (day 720) | ||||

Period | Baseline to Month 18 | Month 18 onwards | Treatment-by-period interaction 2-sided p value | Baseline to Month 24 | Month 24 onwards | Treatment-by-period interaction 2-sided p value |

Combined tofacitinib doses* vs NFi | 0.93 (0.53 to 1.62) | 1.93 (1.22 to 3.06) | 0.0469 | 1.25 (0.75 to 2.07) | 1.70 (1.05 to 2.77) | 0.3864 |

Tofacitinib 5 mg two times per day vs TNFi | 0.99 (0.53 to 1.88) | 1.87 (1.13 to 3.10) | 0.1280 | 1.14 (0.63 to 2.04) | 1.81 (1.06 to 3.09) | 0.2466 |

Tofacitinib 10 mg two times per day vs TNFi | 0.86 (0.44 to 1.67) | 1.99 (1.20 to 3.30) | 0.0477 | 1.36 (0.77 to 2.40) | 1.59 (0.92 to 2.75) | 0.7055 |

In this piecewise exponential hazard model analysis, one change-point is used to divide the timelines into two periods. Log-hazards for the two periods for each treatment were estimated separately by treatment group (combined tofacitinib, tofacitinib 5 mg two times per day, tofacitinib 10 mg two times per day, and TNFi). The HR between tofacitinib versus TNFi was calculated by exponentiation of the log-hazard difference. The 95% CI was estimated assuming large sample approximation. The treatment-by-period interaction 2-sided p-value is based on the difference of the two log-hazard differences (tofacitinib dose group vs TNFi) between the two periods (period 1 vs period 2), using large sample approximation.

For patients randomised to the tofacitinib 10 mg two times per day group who had their dose of tofacitinib reduced to 5 mg two times per day, the data collected after patients were switched to tofacitinib 5 mg two times per day were counted in the tofacitinib 10 mg two times per day group.

For malignancies excluding NMSC, the risk period was total time, defined as time from first dose of trial drug until last contact date.

*Includes patients who received tofacitinib 5 or 10 mg two times per day in ORAL Surveillance.

NMSC, non-melanoma skin cancer; TNFi, tumour necrosis factor inhibitors.